Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
Howard I. Scher, Susan Halabi, Ian F. Tannock et al. · Journal of Clinical Oncology · 2008
PURPOSE: To update eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone. METHODS: A committee of investigators experienced in conducting trials for prostate cancer defined new consensus criteria by reviewing previous criteria, Response Evaluation Criteria in Solid Tumors (RECIST), and emerging trial data. RESULTS: The Prostate Cancer Clinical Trials Working Group (PCWG2) recommends a two-objective paradigm: (1) controlling, relieving, or eliminating disease manifestations that are present when treatment is initiated and (2) preventing or delaying disease manifestations expected to occur. Prostate cancers progressing despite castrate levels of testosterone are considered castration resistant and not hormone refractory. Eligibility is defined using standard disease assessments to authenticate disease progression, prior treatment, distinct clinical subtypes, and predictive models. Outcomes are reported independently for prostate-specific antigen (PSA), imaging, and clinical measures, avoiding grouped categorizations such as complete or partial response. In most trials, early changes in PSA and/or pain are not acted on without other evidence of disease progression, and treatment should be continued for at least 12 weeks to ensure adequate drug exposure. Bone scans are reported as "new lesions" or "no new lesions," changes in soft-tissue disease assessed by RECIST, and pain using validated scales. Defining eligibility for prevent/delay end points requires attention to estimated event frequency and/or random assignment to a control group. CONCLUSION: PCWG2 recommends increasing emphasis on time-to-event end points (ie, failure to progress) as decision aids in proceeding from phase II to phase III trials. Recommendations will evolve as data are generated on the utility of intermediate end points to predict clinical benefit.
Cited by 2,241 works. doi:10.1200/jco.2007.12.4487 Open-access PDF
Authors
- Howard I. Scher
- Susan Halabi
- Ian F. Tannock
- Michael J. Morris
- Cora Nanette Sternberg
- Michael Anthony Carducci
- Mario A. Eisenberger
- Celestia S. Higano
- Glenn J. Bubley
- Robert Dreicer
- Daniel P. Petrylak
- Philip W. Kantoff
- Ethan Basch
- William Kevin Kelly
- William Douglas Figg
- Eric Jay Small
- Tomasz M. Beer
- George Wilding
- Alison L. Martin
- Maha Hussain
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
- Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
- Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group
- Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance
- Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate Cancer
- Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer
- Increased Expression of Genes Converting Adrenal Androgens to Testosterone in Androgen-Independent Prostate Cancer
- Gene Expression Analysis of Human Prostate Carcinoma during Hormonal Therapy Identifies Androgen-Responsive Genes and Mechanisms of Therapy Resistance
- Nomogram for Overall Survival of Patients With Progressive Metastatic Prostate Cancer After Castration